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Abstract: Corifollitropin alfa is a synthetic recombinant follicle-stimulating hormone (rFSH) 
molecule containing a hybrid beta subunit, which provides a plasma half-life of ∼65 hours 
while maintaining its pharmocodynamic activity. A single injection of corifollitropin alfa can 
replace daily FSH injections for the first week of ovarian stimulation for in vitro fertilization. 
Stimulation can be continued with daily FSH injections if the need arises. To date, more than 
2500 anticipated normoresponder women have participated in clinical trials with corifollitropin 
alfa. It is noteworthy that one-third of women did not require additional gonadotropin injec-
tions and reached human chorionic gonadotropin criterion on day 8. The optimal corifollitropin 
dose has been calculated to be 100 µg for women with a body weight #60 kg and 150 µg for 
women with a body weight .60 kg, respectively. Combination of corifollitropin with daily 
gonadotropin-releasing hormone antagonist injections starting on stimulation day 5 seems to 
yield similar or significantly higher numbers of oocytes and good quality embryos, as well as 
similar ongoing pregnancy rates compared with women stimulated with daily rFSH injections. 
Stimulation characteristics, embryology, and clinical outcomes seem consistent with repeated 
corifollitropin-stimulated assisted reproductive technologies cycles. Multiple pregnancy or 
ovarian hyperstimulation syndrome rates with corifollitropin were not increased over daily 
FSH regimen. The corifollitropin alfa molecule does not seem to be immunogenic and does not 
induce neutralizing antibody formation. Drug hypersensitivity and injection-site reactions are not 
increased. Incidence and nature of adverse events and serious adverse events are similar to daily 
FSH injections. Current trials do not provide information regarding use of corifollitropin alfa in 
anticipated hyper- and poor responders to gonadotropin stimulation. Although corifollitropin 
alfa is unlikely to be teratogenic, at the moment data on congenital malformations is missing.
Keywords: follicle-stimulating hormone, long acting, controlled ovarian hyperstimulation, 
in vitro fertilization, assisted reproduction
Introduction
Infertility affects 10%–15% couples trying to conceive.1,2 Assisted reproductive tech-
nologies (ART) provide the highest chance of success for those couples. Although 
the first ART pregnancy was achieved in a natural cycle, it was soon realized that the 
chances of achieving a pregnancy was related to the number of oocytes available for in 
vitro fertilization (IVF).3 Ovarian stimulation with exogenous gonadotropins quickly 
became standard practice. The introduction of gonadotropin-releasing hormone (GnRH) 
agonists (GnRHa) enabled prevention of premature luteinizing hormone (LH) surges 
observed in stimulated cycles and scheduling oocyte retrieval. Thus, controlled ovarian 
hyperstimulation (COS) with its two components, gonadotropin and GnRHa, became 
an integral part of the ART cycle.4 COS proved to increase the success rate of IVF, International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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and the results achieved by most treatment centers exceed 
spontaneous conception rates in healthy fertile couples.5
The long GnRHa protocol has been the most commonly 
used COS protocol for about two decades. While effectively 
preventing premature LH surges and maintaining multifol-
licular growth, the long GnRHa protocol requires approxi-
mately 3 weeks of self injections on the part of the patient. 
Daily GnRHa injections are started from the midluteal 
phase of the preceding cycle, and daily gonadotropin injec-
tions are added within the first week of menstruation. Both 
injections are continued until follicles reach adequate size. 
While GnRHa injections last around 20 days, gonadotropin 
injections last 10–12 days on average, depending on the 
individual ovarian response.
Daily injections for 3 weeks are inconvenient and pos-
sibly contribute to the stress perceived by the patients. 
Indeed, infertile patients experience a high level of distress, 
and their level of anxiety and depression is equivalent to 
that experienced by women with cancer or heart disease.6 
Almost one-third of the couples end treatment prematurely 
because of its psychological burden.7 A high proportion of 
couples drop out even when treatment costs are fully covered 
by third parties. Importantly, when a mild ART strategy was 
employed, the association between the baseline anxiety score 
and drop-out was reduced by .50%.8 Obviously, simpler and 
more convenient treatment strategies improve the overall 
patient experience. Fewer injections may also lessen the 
complexity and psychological burden of IVF.
The first improvement to shorten treatment duration and 
decrease the number of injections was the introduction of 
GnRH antagonists (GnRHant) into ART practice. Different 
from downregulation induced by GnRHa, GnRHant com-
petitively inhibits GnRH activity at the receptor level and 
provides rapid prevention of premature LH surges in COS 
cycles. This enables starting GnRHant injections during the 
actual COS cycle when premature LH surges are imminent. 
GnRHant is started either on day 6 of gonadotropin stimula-
tion or when the leading follicle reaches 14 mm, depending 
on the choice of protocol, and continued until follicular 
maturity. Compared to 3 weeks of GnRHa injections in 
the long protocol, most women only need about 5 days on 
GnRHant injections. The use of GnRHant decreases GnRH 
analog injections by about 2 weeks. The initial concern about 
decreased pregnancy rates with GnRHant has subsided, and 
GnRHant have become the pituitary suppression agent of 
choice in many ART centers worldwide.9,10 In fact, more 
recent patient-friendly, mild-stimulation protocols all utilize 
GnRHant to prevent premature LH surges.
The second development which can further simplify 
ART treatment is the introduction of corifollitropin alfa, 
a long-acting recombinant follicle-stimulating hormone 
(rFSH) molecule. A single injection of corifollitropin alfa 
can replace daily gonadotropin injections for 7 days and 
can further decrease the number of injections required in a 
COS cycle.11–15
In the remainder of this manuscript a brief review of the 
pharmacologic properties of corifollitropin alfa will be fol-
lowed by treatment outcomes of corrifollitropin alfa-stimulated 
ART cycles. The authors of this paper performed a systematic 
literature search in the Cochrane Central Register of Con-
trolled Trials, MEDLINE, EMBASE, and OVID MEDLINE 
In-Process and Other Non-Indexed Citations databases using 
combinations of the keywords corifollitropin alfa, follicle 
stimulating hormone, follicle stimulant, sustained, carboxy 
terminal peptide, Elonva, ovarian stimulation, controlled, and 
IVF. We searched the abstracts of the American Society of 
Reproductive Medicine and the European Society of Human 
Reproduction and Embryology annual meetings through 
websites of ‘Fertility and Sterility’ and ‘Human Reproduction’, 
respectively. Reference lists of identified reports were manually 
searched for other relevant publications.
Corifollitropin alfa – the molecule
FSH belongs to the glycoprotein hormone family. Other 
members are LH, human chorionic gonadotropin (hCG), 
and thyroid-stimulating hormone. Glycoprotein hormones 
are dimeric proteins consisting of two nonidentical, nonco-
valently linked alpha and beta subunits. The alpha subunit is 
common to all family members, whereas the beta subunit is 
unique to each hormone and confers biologic specificity.16,17 
With the exception of hCG, the human glycoprotein hor-
mones have a relatively short terminal half-life (t½) in vivo.16,18 
While terminal t½ of LH and FSH are about 60 minutes and 
3–4 hours, respectively, hCG has a terminal t½ of 25–33 hours. 
Plasma t½ of hCG is nearly 10-fold longer than that of LH.19,20 
The major structural difference between the two molecules 
is the 31 amino acids long C-terminal peptide (CTP) 
that exists in the beta subunit of hCG but not in LH. The 
hCG-CTP includes four additional O-linked carbohydrate 
side chains, each of which has two terminal sialic acid resi-
dues.21 It is the presence of these side chains at the CTP site 
that confers the longest circulating t½ among glycoprotein 
hormones to hCG.22,23 HCG lacking the CTP sequence has 
three-fold less bioactivity than native hCG.22 Glycosylation 
of the CTP increases the plasma t½ of hCG by reducing 
glomerular filtration within the kidney.16,23–25International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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The relatively short t½ of the wild-type FSH molecule 
(WT-FSH) requires once daily dosing for COS. Several dif-
ferent approaches have been used to develop an FSH prepara-
tion with a longer plasma t½. Initially it has been suggested 
that increasing the molecular weight and glycosylation of 
the WT-FSH could generate more negatively charged forms 
and decrease glomerular filtration of FSH. Thus, the circu-
lating t½ of the hormone could be prolonged secondary to a 
decrease in renal clearance. Indeed, increasing the number 
of glycosylation sites on the FSH molecule with either N- 
or O-linked moieties extended the plasma t½ as much as 
two-fold compared with human rFSH.26,27 However, after a 
certain point it was not possible to further extend plasma t½ 
by glycosylation.27
Boime and colleagues took a novel approach and 
fused copies of CTP of hCG beta-subunit to the FSH beta-
subunit.28,29 They constructed chimeric genes containing the 
sequence encoding the CTP of hCG beta subunit fused to 
the sequence of the human FSH beta subunit. The new FSH 
beta-CTP sequence was transfected into Chinese hamster 
ovary (CHO) cells together with the wild-type alpha subunit 
sequence. Compared to the WT-FSH sequence, the addition 
of CTP sequences did not significantly affect assembly, secre-
tion, or stimulation of steroidogenesis in vitro. However, the 
in vivo potency of the chimera-containing CTP (FSH-CTP, 
corifollitropin alfa) was substantially increased.28 Corifol-
litropin alfa was found to be 10-fold more biopotent than 
WT-FSH.29 One study demonstrated that a single injection of 
10 IU corifollitropin alfa was sufficient to stimulate follicle 
maturation in rats, such that ovulation could be induced by 
hCG 52 hours later. In contrast, a single injection of 10 IU 
WT-FSH was ineffective in increasing ovulatory potential, 
whereas the same total dose of WT-FSH, administered as four 
separate 2.5 IU injections 12 hours apart, was as effective as 
corifollitropin alfa.29 These results indicate that maintenance 
of serum FSH level above the threshold value required to 
stimulate follicular growth is more important than total dose 
administered.29
Importantly, corifollitropin alfa was found to interact only 
with the FSH-receptor and lacked any LH activity.26,29,30
Pharmacokinetics
Animal studies have shown that corifollitropin alfa has a 
comparable pharmacological activity and a prolonged plasma 
t½ compared with rFSH.28,29 Because of its long t½, standard-
ization of corifollitropin alfa activity by means of the clas-
sical Steelman–Pohley bioassay does not provide a reliable 
estimate of its in vivo bioactivity from a pharmacological or 
clinical perspective.12,31 Therefore, pure recombinant corifol-
litropin alfa dosages are expressed in mass (micrograms) 
instead of international units.12
Phase I studies
The first human study was conducted in men with hypogonad-
otropic hypogonadism.32 The plasma t½ of corifollitropin alfa 
in humans was found to be 94.7 ± 26.2 hours, approximately 
two- to three-fold longer than the t½ of rFSH.32 The plasma 
t½ of rFSH has been shown to be ∼34 ± 5 hours in pituitary-
suppressed females.33 Compared with rFSH, corifollitropin 
alfa absorption appeared to be slow, with a time to maximal 
serum concentration (tmax) of 46 ± 18 hours after injection. 
RFSH reaches maximal serum concentrations by 13 ± 6 hours 
after a subcutaneous injection in women.33
The first corifollitropin alfa study in women involved 24 
healthy women who underwent pituitary suppression with a 
combined oral contraceptive pill (OCP).11 Participants were 
given a single dose of 15, 30, 60, or 120 µg of corifollitropin 
alfa on the 21st day of OCP. The median tmax was 36 hours 
in the 15, 60, and 120 µg groups, and 48 hours in the 30 µg 
group. Plasma t½ ranged between 60 hours in the 30 µg group 
and 75 hours in the 120 µg group. After normalizing for the 
dosage administered, both tmax and t½ were found to be dose 
independent within the dose range tested.11 Earlier studies 
evaluating pharmacokinetics of rFSH in healthy women who 
had pituitary suppression with the same OCP reported that 
tmax was 17 hours after a single 300 IU dose of rFSH,34 and 
varied between 7.5 and 8.5 hours following daily injections 
of rFSH at doses of 75, 150, or 225 IU for 7 days.35 T½ of 
rFSH was reported to be 34.8–36.2 hours in the same study.35 
In another study, t½ of rFSH was 37 hours following a single 
150 IU injection and 24 hours after 7 days of daily 150 IU 
injections in pituitary-suppressed women.36
Based on the abovementioned results, absorption of 
corifollitropin alfa appears to be slower than that of rFSH. 
The reason for slower absorption can be the larger size of 
the corifollitropin alfa molecule than the rFSH molecule. 
Regardless, plasma t½ for corifollitropin alfa is consistently 
longer, reaching twice t½ of rFSH in healthy women with 
pituitary suppression.
Phase II studies
In a double-blind, placebo-controlled, randomized trial, 55 
oligo-amenorrheic women with World Health Organiza-
tion Group II anovulatory infertility were randomized to 
receive either a single injection of 7.5, 15, 30, or 60 µg 
corifollitropin alfa or placebo on day 2–3 of a spontaneous International Journal of Women’s Health 2011:3
Table 1 Pharmacokinetic characteristics of recombinant FSH preparations
Population FSH preparation Dose tmax (hours) t½ (hours)
Healthy women with pituitary suppression11 Corifollitropin alfa 120 µg 36.0 74.5
Women with WHO class II anovulation37 Corifollitropin alfa 60 µg 26.5 83.9
Normo-ovulatory women undergoing IvF13 Corifollitropin alfa 120 µg 41.2 65.3
Normo-ovulatory women ,60 kg undergoing IvF15 Corifollitropin alfa 100 µg 46.2 73.1
Normo-ovulatory women undergoing IvF14 Corifollitropin alfa 150 µg 43.8 68.2
Gonadotropin deficient women34 Recombinant FSH 300 IU 27.0 44.0
Gonadotropin deficient women34 Urinary FSH 300 IU 21.0 38.0
Healthy women with pituitary suppression34 Recombinant FSHa 150 IU 10.6 30.6
Notes: aDaily administration for 7 days. All values after a single dose administration unless otherwise stated.
Abbreviations: FSH, follicle-stimulating hormone; IvF, in-vitro fertilization; tmax, time to reach maximal serum concentration; t½, plasma half life; WHO, World Health 
Organization.
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or progestagen-induced menstrual bleeding.37 While tmax was 
consistently around 26.0–28.6 hours in all groups, the mean 
plasma t½ ranged between 77 and 86 hours in the 15, 30, 
and 60 µg groups, but it was 110 hours in the 7.5 µg group. 
The dose-normalized measures of individual exposure to 
corifollitropin alfa, calculated with maximal serum con-
centration (Cmax) and the area under the curve (AUC) after 
taking into account individual total serum clearance and 
volume of distribution were similar for the 15, 30, and 60 µg 
doses. These findings show that the serum concentration of 
corifollitropin alfa is proportional to the dose within the 
15–60 µg dose range. The relatively longer plasma t½ of the 
corifollitropin alfa after a 7.5 µg dose observed in this study 
was due to lower serum clearance observed in this group. 
The investigators suggested that this was a “chance finding” 
and plasma t½ was independent from the dose given.37 These 
results shows that pharmacokinetics of corifollitropin alfa 
is similar in anovulatory women and healthy women with 
pituitary suppression, and it is not affected by the endocrine 
status of recipient.
To date, corifollitropin alfa, in doses ranging 60–240 µg, 
has been given to some 2000 women undergoing IVF 
treatment in the context of randomized controlled trials 
(RCT).12–15,38 All these studies have used GnRHant to pre-
vent premature LH surges. The pharmokinetic parameters of 
corifollitropin alfa in IVF patients seem to be consistent with 
the previous studies, with Cmax being reached on day 2 after 
injection (tmax 25–46 hours) and plasma t½ being approxi-
mately 65 hours.11,32,37 The dose-normalized AUC and dose-
normalized Cmax values were similar across the dose range 
used in these trials. These trials also demonstrated Cmax and 
AUC values for corifollitropin alfa were dose-proportional 
for doses ranging from 60 to 240 µg.13,38,39
Corifollitropin alfa exposure showed an inverse relation-
ship with bodyweight, which was found to be a significant 
covariate of clearance and volume of distribution.13 Cmax and 
AUC were calculated to be almost twice as high in a woman 
with 50 kg bodyweight (5.12 ng/mL and 735 ng⋅h/mL) com-
pared with a woman who has a bodyweight of 80 kg (2.67 ng/
mL and 402 ng⋅h/mL).13
Pharmacokinetic characteristics of corifollitropin are 
summarized in Table 1.
Clinical trials of corifollitropin  
in ART cycles
The first live birth following the use of corifollitropin alfa 
for COS in an ART cycle was reported in a woman who had 
primary infertility for 7 years.40 She received a single 180 µg 
dose of corifollitropin alfa on cycle day 3, which was fol-
lowed by daily rFSH injections from day 10 of stimulation 
until hCG administration. GnRHant was used for pituitary 
suppression. Twelve oocytes were retrieved, 10 were fertil-
ized, and two embryos were transferred, and the patient had 
a singleton live birth at term. The use of corifollitropin alfa 
in COS-IVF cycles has been evaluated in four RCTs.12–15 The 
efficacy and safety of repeated COS cycles with corifollitro-
pin was evaluated in a prospective cohort study.41
All four RCTs have recruited women with regular men-
strual periods and younger than 40 years of age. Women who 
were underweight or obese according to body mass index,12–15 
had polycystic ovarian syndrome (PCOS),12–15 had high 
antral follicle count (.20),14,15 had elevated follicular phase 
serum FSH level,14,15 had a history of over or poor response 
to gonadotropin stimulation,13–15 had recurrent miscarriage 
or recurrent implantation failure,13–15 had oopherectomy,13–15 
or smoked .5 cigarettes/day were excluded.14,15
Pituitary suppression was achieved with GnRHant in 
all trials, albeit starting day of GnRHant varied in one trial. 
When women allocated to corifollitropin alfa needed further 
stimulation to reach hCG criterion, they received daily rFSH 
injections from stimulation day 8 on, with dosage   depending 
on the individual trial protocol. HCG administration   criterion International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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was uniform across the trials, ie, three or more follicles 
$17 mm.
Number and size of ovarian follicles were assessed with 
serial ultrasound examinations. Blood samples were drawn 
for assessment of serum FSH, LH, estradiol (E2), inhibin B, 
and progesterone levels during the stimulation period as well 
as during the luteal phase in one trial. Relevant characteristics 
of the four RCTs are described in Table 2.
A brief description of individual trials will be followed 
by the results for different outcome measures.
The feasibility study (FS)12
The first RCT was a Phase II FS evaluating the efficacy 
and safety of corifollitropin alfa in COS-IVF.12 A total of 
98 women were randomized to receive a 120 (n = 25), 180 
(n = 24), or 240 µg (n = 25) injection of corifollitropin alfa 
on cycle day 2 or 3. Women who did not reach hCG criterion 
on day 8 received 150 IU/day rFSH injections from stimula-
tion day 8 onwards. Women allocated to the control group 
(n = 24) received 150 IU/day rFSH injections from the start. 
Daily GnRHant injections were started on the day when the 
leading follicle reached $14 mm size. Up to three embryos 
were transferred on day 3 or 5 after fertilization.
The dose-finding study (DFS)13
The second RCT was a DFS evaluating three different doses 
of corifollitropin alfa.13 The investigators attributed the 
failure to demonstrate a strong dose response effect in the 
FS12 to the high dose range tested and therefore decreased 
corifollitropin alfa dose to 60, 120, and 180 µg for the 
DFS. A total of 315 women were randomized and received 
a single injection of 60 µg corifollitropin alfa (n = 78), 
120 µg corifollitropin alfa (n = 77), 180 µg corifollitropin 
alfa (n = 79), or daily injections of 150 IU rFSH (n = 81) 
from cycle day 2–3. If women allocated to corifollitropin 
alfa needed further stimulation to meet the hCG criterion, 
they received a fixed dose of 150 IU/day rFSH from stimula-
tion day 8 onwards. Daily GnRHant injections were started 
on stimulation day 5 due to a relatively high incidence of 
premature LH surges observed with the flexible GnRHant 
protocol used in the FS.12 The incidence of premature LH 
surges will be mentioned further on in the Hormonal Profiles 
section. Up to three embryos were transferred 3–5 days after 
fertilization.
The eNGAGe trial14
The third RCT was the ENGAGE trial, a multicenter, 
randomized, double-blind, double-dummy, noninferiority 
clinical trial investigating whether ongoing pregnancy rate 
(defined as .12 weeks pregnancy with fetal heart beat) 
achieved with a corifollitropin alfa regimen was within 
8% noninferiority margin compared with a standard daily 
rFSH regimen.14 While the FS12 and the DFS13 were mainly 
Phase II trials which had a focus on the number of oocytes 
collected, ENGAGE was the first Phase III trial aimed to 
test ongoing pregnancy rates against a daily rFSH regi-
men. Based on the results obtained in the previous trials, 
the lowest corifollitropin alfa dose necessary to obtain an 
optimal treatment outcome was calculated to be 100 µg for 
women weighing #60 kg and 150 µg for women weigh-
ing .60 kg.42 The ENGAGE trial recruited women weigh-
ing .60 kg up to and including 90 kg. Women received 
either 150 µg corifollitropin alfa (n = 756) or started 200 
IU/day rFSH injections (n = 750) on cycle day 2–3. Notably, 
ENGAGE was the largest double-blind RCT ever conducted 
in the field of ART. Dose reduction was allowed from day 5 
of stimulation for women who were deemed over-respond-
ing to stimulation by the local investigators, but due to the 
double-dummy design, women in the corifollitropin alfa 
group would actually have placebo dose reduced between 
days 5–8. GnRHant injections were started on stimulation 
day 5. The maximum rFSH dose allowed was 200 IU/day 
for women who needed stimulation after day 7. Coasting 
was allowed up to 3 days, but the hCG injection had to be 
withheld for women who had .30 follicles of $11 mm 
in any case. Up to two embryos were transferred 3–5 days 
after fertilization.
The eNSURe trial15
The fourth study was the ENSURE trial,15 which had the 
same design features as the ENGAGE trial, ie, double-
blind, double-dummy, placebo-controlled RCT with the 
same inclusion and exclusion criteria. Different than 
the ENGAGE, the ENSURE trial recruited women who 
weighed #60 kg. According to the previously mentioned 
calculations, 268 women allocated to the corifollitropin 
alfa group received a 100 µg injection, while 128 women 
allocated to the rFSH group started 150 IU/day injections 
on cycle days 2–3. Dose adjustments were allowed from 
stimulation day 6 on. The maximum allowed daily rFSH 
dosage was 200 IU. GnRHant injections were started on 
day 5 of stimulation. Similar to the ENGAGE trial, coasting 
was allowed up to 3 days, but hCG injection had to be with-
held for women who had .30 follicles of $11 mm in any 
case. Up to two embryos were transferred 3–5 days after 
fertilization.International Journal of Women’s Health 2011:3
T
a
b
l
e
 
2
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
r
a
n
d
o
m
i
z
e
d
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
s
 
o
f
 
c
o
r
i
f
o
l
l
i
t
r
o
p
i
n
 
s
t
i
m
u
l
a
t
i
o
n
 
f
o
r
 
I
v
F
F
e
a
s
i
b
i
l
i
t
y
 
s
t
u
d
y
1
2
D
o
s
e
-
fi
n
d
i
n
g
 
s
t
u
d
y
1
3
E
N
G
A
G
E
1
4
E
N
S
U
R
E
1
5
I
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
1
8
–
3
9
 
y
e
a
r
s
 
o
f
 
a
g
e
 
B
M
I
 
1
8
–
2
9
 
k
g
/
m
2
 
R
e
g
u
l
a
r
 
m
e
n
s
t
r
u
a
l
 
c
y
c
l
e
s
a
2
0
–
3
9
 
y
e
a
r
s
 
o
f
 
a
g
e
 
B
M
I
 
1
7
–
3
1
 
k
g
/
m
2
 
R
e
g
u
l
a
r
 
m
e
n
s
t
r
u
a
l
 
c
y
c
l
e
s
a
1
8
–
3
6
 
y
e
a
r
s
 
o
f
 
a
g
e
 
B
M
I
 
1
8
–
3
1
 
k
g
/
m
2
 
B
o
d
y
w
e
i
g
h
t
 
.
 
6
0
 
k
g
 
b
u
t
 
#
9
0
 
k
g
 
R
e
g
u
l
a
r
 
m
e
n
s
t
r
u
a
l
 
c
y
c
l
e
s
a
 
A
c
c
e
s
s
 
t
o
 
e
j
a
c
u
l
a
t
o
r
y
 
s
p
e
r
m
1
8
–
3
6
 
y
e
a
r
s
 
o
f
 
a
g
e
 
B
M
I
 
1
8
–
3
1
 
k
g
/
m
2
 
 
B
o
d
y
w
e
i
g
h
t
 
#
 
6
0
 
k
g
 
R
e
g
u
l
a
r
 
m
e
n
s
t
r
u
a
l
 
c
y
c
l
e
s
a
 
A
c
c
e
s
s
 
t
o
 
e
j
a
c
u
l
a
t
o
r
y
 
s
p
e
r
m
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
N
A
P
C
O
S
,
 
,
2
 
o
v
a
r
i
e
s
,
 
e
n
d
o
c
r
i
n
e
 
 
a
b
n
o
r
m
a
l
i
t
y
,
 
h
i
s
t
o
r
y
 
o
f
 
O
H
S
S
,
 
 
p
o
o
r
 
r
e
s
p
o
n
s
e
 
t
o
 
g
o
n
a
d
o
t
r
o
p
i
n
,
 
 
$
3
 
p
r
e
v
i
o
u
s
 
I
v
F
 
f
a
i
l
u
r
e
b
P
C
O
S
,
 
e
n
d
o
c
r
i
n
e
 
a
b
n
o
r
m
a
l
i
t
y
,
 
c
h
r
o
n
i
c
 
d
i
s
e
a
s
e
,
 
 
a
b
n
o
r
m
a
l
 
c
e
r
v
i
c
a
l
 
s
m
e
a
r
,
 
o
v
a
r
i
a
n
/
t
u
b
a
l
/
u
t
e
r
i
n
e
 
 
p
a
t
h
o
l
o
g
y
,
c
 
h
i
g
h
 
o
r
 
l
o
w
 
o
v
a
r
i
a
n
 
r
e
s
e
r
v
e
,
d
 
$
5
 
 
c
i
g
a
r
e
t
t
e
s
/
d
a
y
,
 
h
i
s
t
o
r
y
 
o
f
:
 
O
H
S
S
,
 
p
o
o
r
 
r
e
s
p
o
n
s
e
 
t
o
 
 
g
o
n
a
d
o
t
r
o
p
i
n
,
 
$
3
 
p
r
e
v
i
o
u
s
 
I
v
F
 
f
a
i
l
u
r
e
,
b
 
r
e
c
u
r
r
e
n
t
 
 
m
i
s
c
a
r
r
i
a
g
e
P
C
O
S
,
 
e
n
d
o
c
r
i
n
e
 
a
b
n
o
r
m
a
l
i
t
y
,
 
c
h
r
o
n
i
c
 
 
d
i
s
e
a
s
e
,
 
a
b
n
o
r
m
a
l
 
c
e
r
v
i
c
a
l
 
s
m
e
a
r
,
 
 
o
v
a
r
i
a
n
/
t
u
b
a
l
/
u
t
e
r
i
n
e
 
p
a
t
h
o
l
o
g
y
,
 
h
i
g
h
 
o
r
 
 
l
o
w
 
o
v
a
r
i
a
n
 
r
e
s
e
r
v
e
,
d
 
$
5
 
 
c
i
g
a
r
e
t
t
e
s
/
d
a
y
,
 
h
i
s
t
o
r
y
 
o
f
:
 
O
H
S
S
,
 
p
o
o
r
 
 
r
e
s
p
o
n
s
e
 
t
o
 
g
o
n
a
d
o
t
r
o
p
i
n
,
 
$
3
 
p
r
e
v
i
o
u
s
 
 
I
v
F
 
f
a
i
l
u
r
e
,
b
 
r
e
c
u
r
r
e
n
t
 
m
i
s
c
a
r
r
i
a
g
e
C
o
r
i
f
o
l
i
t
r
o
p
i
n
 
d
o
s
a
g
e
1
2
0
 
µ
g
,
 
1
8
0
 
µ
g
,
 
2
4
0
 
µ
g
6
0
 
µ
g
,
 
1
2
0
 
µ
g
,
 
1
8
0
 
µ
g
1
5
0
 
µ
g
1
0
0
 
µ
g
C
o
m
p
a
r
a
t
o
r
1
5
0
 
I
U
/
d
 
r
F
S
H
1
5
0
 
I
U
/
d
 
r
F
S
H
2
0
0
 
I
U
/
d
 
r
F
S
H
 
(
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
 
a
f
t
e
r
 
d
a
y
 
5
)
1
5
0
 
I
U
/
d
 
r
F
S
H
 
(
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
 
 
a
f
t
e
r
 
d
a
y
 
6
)
G
n
R
H
a
n
t
 
s
t
a
r
t
 
t
i
m
e
L
e
a
d
i
n
g
 
f
o
l
l
i
c
l
e
 
$
 
1
4
 
m
m
D
a
y
 
5
 
o
f
 
s
t
i
m
u
l
a
t
i
o
n
D
a
y
 
5
 
o
f
 
s
t
i
m
u
l
a
t
i
o
n
D
a
y
 
5
 
o
f
 
s
t
i
m
u
l
a
t
i
o
n
r
F
S
H
 
d
o
s
e
 
f
o
r
 
 
c
o
n
t
i
n
u
i
n
g
 
s
t
i
m
u
l
a
t
i
o
n
 
 
a
f
t
e
r
 
c
o
r
i
f
o
l
l
i
t
r
o
p
i
n
r
F
S
H
 
1
5
0
 
I
U
/
d
 
fi
x
e
d
r
F
S
H
 
1
5
0
 
I
U
/
d
 
fi
x
e
d
2
0
0
 
I
U
/
d
 
o
r
 
l
e
s
s
2
0
0
 
I
U
/
d
 
o
r
 
l
e
s
s
N
o
t
e
s
:
 
a
2
4
–
3
5
 
d
a
y
s
;
 
b
a
f
t
e
r
 
t
h
e
 
l
a
s
t
 
e
s
t
a
b
l
i
s
h
e
d
 
o
n
g
o
i
n
g
 
p
r
e
g
n
a
n
c
y
;
 
c
w
h
i
c
h
 
c
o
u
l
d
 
a
f
f
e
c
t
 
r
e
s
p
o
n
s
e
 
t
o
 
o
v
a
r
i
a
n
 
s
t
i
m
u
l
a
t
i
o
n
 
o
r
 
e
m
b
r
y
o
 
i
m
p
l
a
n
t
a
t
i
o
n
;
 
d
h
i
g
h
 
o
v
a
r
i
a
n
 
r
e
s
e
r
v
e
 
d
e
fi
n
e
d
 
a
s
 
b
i
l
a
t
e
r
a
l
 
b
a
s
a
l
 
a
n
t
r
a
l
 
f
o
l
l
i
c
l
e
 
c
o
u
n
t
 
o
f
 
.
2
0
 
a
n
d
 
l
o
w
 
o
v
a
r
i
a
n
 
r
e
s
e
r
v
e
 
d
e
fi
n
e
d
 
a
s
 
f
o
l
l
i
c
u
l
a
r
 
p
h
a
s
e
 
s
e
r
u
m
 
F
S
H
 
o
r
 
L
H
 
l
e
v
e
l
 
.
 
1
2
 
I
U
/
L
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
B
M
I
,
 
b
o
d
y
 
m
a
s
s
 
i
n
d
e
x
;
 
F
S
H
,
 
f
o
l
l
i
c
l
e
-
s
t
i
m
u
l
a
t
i
n
g
 
h
o
r
m
o
n
e
;
 
G
n
R
H
a
n
t
,
 
g
o
n
a
d
o
t
r
o
p
i
n
-
r
e
l
e
a
s
i
n
g
 
h
o
r
m
o
n
e
 
a
n
t
a
g
o
n
i
s
t
s
;
 
I
v
F
,
 
i
n
-
v
i
t
r
o
 
f
e
r
t
i
l
i
z
a
t
i
o
n
;
 
L
H
,
 
l
u
t
e
i
n
i
z
i
n
g
 
h
o
r
m
o
n
e
;
 
N
A
,
 
n
o
t
 
a
v
a
i
l
a
b
l
e
;
 
O
H
S
S
,
 
o
v
a
r
i
a
n
 
h
y
p
e
r
s
t
i
m
u
l
a
t
i
o
n
 
s
y
n
d
r
o
m
e
;
 
P
C
O
S
,
 
p
o
l
y
c
y
s
t
i
c
 
o
v
a
r
i
a
n
 
s
y
n
d
r
o
m
e
;
 
r
F
S
H
,
 
r
e
c
o
m
b
i
n
a
n
t
 
f
o
l
l
i
c
l
e
-
s
t
i
m
u
l
a
t
i
n
g
 
h
o
r
m
o
n
e
.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
248
Seyhan and AtaInternational Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
249
Corifollitropin for ART
The TRUST trial41
The TRUST trial was a prospective multicenter, open-
label, uncontrolled clinical trial. The inclusion criteria and 
stimulation protocol were similar to the ENGAGE trial.14 A 
total of 682 women .60 kg were recruited and underwent 
between one and three stimulated ART cycles and no more 
than six frozen thawed embryo transfer cycles from the first 
two treatment cycles. The number of women starting the   
first, second, and third COS cycles were 682, 375, and 198, 
respectively. Corifolitropin dose was 150 µg, and stimulation 
was continued with maximum of 225 IU/day rFSH from day 
8 onwards. GnRHant was started on stimulation day 5 or 6. A 
maximum of three embryos were transferred 3–5 days after 
fertilization in fresh cycles. The results of the TRUST trials 
will be mentioned separately at the end of the next section.
Outcomes
Figures for embryology and clinical outcomes from the four 
RCTs are presented in Table 3.
Follicular growth and oocyte yield
The median duration of stimulation was similar at between 
9 and 11 days in all groups of the four trials.12–15 The FS and 
the DFS reported detailed analysis of follicles of $11 mm, 
$15 mm, and $17 mm during the stimulation period. These 
trials had a focus on comparisons between different doses 
of corifollitropin alfa.
In the FS, the number of follicles $11 mm did not signifi-
cantly differ between study groups throughout the stimulation 
period. Although the number of follicles in each size category 
tended to increase with increasing corifollitropin alfa dose, 
the dose–response relationship was only significant for fol-
licles $15 mm on the day of hCG. In the overall analysis 
including all women who received hCG, regardless of the day 
of administration, the numbers of follicles in each category 
was similar across all study groups. However, in a subgroup 
analysis including women who already met the hCG criterion 
on day 8, women in the 120 µg group had significantly less 
follicles of $15 mm and $17 mm, and women in the 180 µg 
group had significantly less follicles of $17 mm compared 
with the rFSH group.
One woman in each corifollitropin alfa group (overall 
3/74, 4%) and one in the rFSH group (1/25, 4%) had cycle 
cancellation due to poor ovarian response either before or 
after hCG administration. One woman in the 120 µg group 
and one in the 240 µg group had cycle cancellation due to 
over response. The number of oocytes collected was similar 
for corifollitropin alfa groups and tended to be higher than 
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women given daily rFSH injections. The failure to observe a 
dose–response relationship across corifollitropin alfa groups 
was attributed to the high dose range used in the trial.
While the number and size of the follicles were similar 
at the initial assessment between the arms of the DFS, the 
number of follicles $11 mm was less in the 60 µg group than 
in the 120 and 180 µg groups from day 6 on.13 Accordingly, 
a high proportion of participants in the 60 µg group (22/78, 
28.2%) were not given hCG and had their cycle cancelled 
due to insufficient ovarian response. The same figures were 
2/77 (2.6%), 3/79 (3.8%), and 5/81 (6.2%) in the 120 µg, 
180 µg, and rFSH groups respectively. While all women 
who received hCG injection proceeded to fertilization in the 
120 and 180 µg groups, five women in the 60 µg group and 
two women in the rFSH group had their cycle cancelled due 
to having too few follicles/oocytes after the hCG injection. 
Overall number of women having cycle cancellation due to 
low ovarian response summed up to 27/78 (34.6%) in the 
60 µg group. On the other hand, two women (2.6%) in the 
120 µg and one woman (1.3%) in the 180 µg group had 
cycle cancellation before hCG administration due to risk 
of hyperstimulation. No woman in the 60 µg corifollitropin 
alfa or daily rFSH groups were considered at risk of hyper-
stimulation. The dose–response relationship between follicle 
counts and corifollitropin alfa dose reached significance by 
day 8 and was still apparent on the day of hCG injection. 
Compared with the rFSH group, the number of follicles in 
each size category tended to be higher in the 120 and 180 µg 
corifollitropin alfa groups.
The order of the study groups according to number of 
cumulus corona complexes (COC) collected per started cycle 
was 60 µg , rFSH , 120 µg , 180 µg, with statistically 
significant differences between categories. Trend analysis 
demonstrated a significant dose–response relationship 
between corifollitropin alfa dose and the number of COCs 
retrieved (P , 0.0001).
Based on the results from the two studies, it was decided 
that the appropriate dose for a single injection of corifollitro-
pin alfa would be higher than 60 µg and less than 240 µg in 
women with an anticipated normal ovarian response. A pre-
dictive pharmacokinetic and pharmacodynamic modeling 
study was conducted using data from 2667 women who 
received corifollitropin alfa before, and it was suggested 
that the optimal dose, defined as the lowest dose providing 
the minimal cancellation rate, would be 100 µg for women 
#60 kg and 150 µg for women weighing .60 kg.42
Using the doses suggested by the modeling study, women 
given 150 µg corifollitropin alfa in the ENGAGE trial and 
women given 100 µg corifollitropin alfa in the ENSURE trial 
had significantly more follicles of $11 mm on hCG day than 
their counterparts who started stimulation with 200 and 150 
IU/day rFSH injections in respective trials.14,15 While dose 
decreases before day 7 were more commonly attempted in 
the corifollitropin alfa groups than in the daily FSH group 
in both trials (11.3% versus 8.4% in the ENGAGE trial, 
and 6.4% versus 0.8% in the ENSURE trial), the proportion 
of women undergoing coasting for $2 days were similar 
between the two arms of the ENGAGE trial (1.6% versus 
2.2%). Women in the corifollitropin alfa groups had signifi-
cantly more COCs collected per started cycle than women 
who started stimulation with daily rFSH injections in both 
trials.14,15 Estimated differences were +1.2 and +2.7 COCs in 
the ENGAGE and ENSURE trials, respectively (P , 0.001 
for both comparisons). Notably, one-third of women in the 
corifollitropin alfa arms (32.9% and 32.8% in the ENGAGE 
and the ENSURE trials, respectively) reached the hCG cri-
terion before or on day 8 and did not require additional FSH 
injections. Pregnancy rate was 44% for such women in the 
ENGAGE trial.
Hormonal profiles
Serum FSH immunoreactivity increased rapidly until stimu-
lation day 3 (post injection day 2) in recipients of corifol-
litropin alfa. The peak level depended on the corifollitropin 
alfa dose administered and exceeded the peak levels achieved 
in recipients of daily rFSH in both ENGAGE and ENSURE 
trials. There were no significant differences between serum 
FSH levels in corifollitropin alfa and rFSH groups from day 
8 onward.14,15
Serum E2 levels tended to increase faster follow-
ing corifollitropin alfa injection than after daily rFSH 
injections.12–15 This is consistent with the higher serum FSH 
levels and higher number of follicles $11 mm observed 
in the corifollitropin alfa arms during the initial days of 
stimulation. On stimulation day 8, serum E2 levels had a 
dose–response relationship with corifollitropin alfa dose.13 
However serum E2 levels on the day of hCG injection was 
not significantly different between corifollitropin alfa and 
rFSH groups.12–15
Inhibin B levels followed a similar pattern with serum E2 
levels in all trials, and consistently increased during the first 
6 days of stimulation. Similar to E2 levels, inhibin B levels 
were similar between corifollitropin alfa and daily rFSH 
regimens. The only exception was the sharp decline after 
day 6 in the 60 µg corifollitropin alfa arm of the DFS.13 This 
observation is consistent with a lower number of growing International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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follicles in recipients of the 60 µg dose and further confirms 
that this dose is inadequate for COS.
LH levels declined rapidly after corifollitropin alfa 
injection in all groups. However, women who received the 
240 µg dose had increasing LH levels from the third day after 
corifollitropin alfa injection.12 Similar to women receiving 
lower corifollitropin doses, LH levels declined following 
commencement of GnRHant injections in these women. With 
the flexible GnRHant protocol used in the FS, LH rises before 
the start of the GnRHant injections were observed in 12 of 
74 women (16.2%) who received corifollitropin alfa and 
in 2 of 24 women (8.3%) who had daily rFSH injections.12 
Although the incidence of premature LH surges before start-
ing GnRHant was not significantly different between the 
groups, this has led to starting GnRHant injections on the 
fifth day of stimulation in the following trials. Despite the 
early start of GnRHant, a premature LH rise of $10 IU/L 
was detected by day 5 in 12 of the 234 (5.1%) women in the 
corifollitropin alfa arms of the DFS.13 None of the women 
in the rFSH arm had a premature LH rise before GnRHant 
injection in the same study. Notably, three women in the 
corifollitropin alfa arms and two in the rhFSH arm had a 
premature LH rise after GnRHant injections.13
The incidence of premature LH rises were 7% versus 
2.1% (P , 0.01) and 5.2% versus 3.9% (P = 0.57) in the 
corifollitropin alfa and rFSH arms of the ENGAGE and 
ENSURE trials, respectively.14,15 The pregnancy rates for 
women with premature LH rises were not significantly dif-
ferent between corifollitropin alfa (45.3%) and rFSH (31.3%) 
groups of the ENGAGE trial.14
The higher incidence of premature LH rises observed 
in the corifollitropin alfa groups seems to result from the 
higher FSH exposure during the early follicular phase. 
Similar observation has been reported when women with 
high ovarian reserve were given higher starting dose of daily 
rFSH injections in earlier trials evaluating GnRHant.38,43,44 
The ENGAGE investigators regarded any impact of the 
higher incidence of LH rises in the corifollitropin alfa group 
negligible based on pregnancy rates achieved in women 
with a premature LH rise being similar to overall preg-
nancy rates achieved in the aforementioned early GnRHant 
trials.43,44
Progesterone levels remained low throughout the stimu-
lation period in all corifollitropin alfa groups and were not 
significantly different than women who received daily FSH 
injections. Likewise, luteal phase hormone profiles were not 
significantly different between corifollitropin alfa and rFSH 
groups.12,14,15
embryology laboratory parameters
Fertilization rate was similar across different doses of corifol-
litropin alfa, as well as between corifollitropin alfa and rFSH 
groups in all trials.12–15
Although the number of embryos available tended to be 
higher in corifollitropin alfa arms (especially in the 120 µg 
arm) of the FS, the numbers of good quality embryos were 
similar across all groups including the rFSH group.12 Women 
in the 120 and 180 µg arms of the DFS had significantly 
higher numbers of total embryos and good quality embryos 
than women in the rFSH arm.13 These findings are in accor-
dance with the trend towards higher numbers of COCs 
retrieved in these groups. The numbers of embryos available 
and good quality embryos were similar in corifollitropin alfa 
and rFSH arms of the ENGAGE and the ENSURE trials.14,15 
The mean number (standard deviation) of embryos cryopre-
served in the corifollitropin alfa and the rFSH groups were 
4.3 (3.6) versus 3.9 (2.7) and 2.0 (3.0) versus 1.7 (2.6) in the 
ENGAGE and the ENSURE trials respectively.14,15
Clinical outcome
Despite the lack of a statistically significant difference 
between ongoing pregnancy rates between the four arms of 
the FS (P = 0.19), it should be noted that when all women in 
the corifollitropin alfa groups were compared with women 
in the rFSH group, the difference in ongoing pregnancy 
rates was significant (15/74, 20.3% versus 10/24, 41.6%; 
P = 0.04).12 However, it should also be noted that the high 
ongoing pregnancy rate achieved in the rFSH arm, despite 
lower number of oocytes retrieved, is extraordinary and could 
be a chance finding.
Incidence of vital pregnancy (defined as pregnancy with 
at least one fetus with a heart beat . 12 gestational weeks) 
and ongoing pregnancy rates per cycle and per transfer was 
similar in the four arms of the DFS.13 Ongoing pregnancy 
rate per fresh cycle ranged between 16% and 24% in the 
corifollitropin alfa arms of the FS and the DFS.12,13 Cumu-
lative ongoing pregnancy rate including transfer of frozen 
thawed embryos obtained from the index cycle within a year 
was only reported in the DFS, and figures were 18% in the 
60 µg, 27% in the 120 µg, 24% in the 240 µg corifollitropin 
alfa groups, and 20% in the daily rFSH group.13
Overall, higher ongoing pregnancy rates were achieved 
in the ENGAGE trial, which used the corifollitropin alfa 
dose adjusted for bodyweight and a higher starting dose of 
daily rFSH injections.14 Ongoing pregnancy rate per cycle 
was similar at 38.9% and 38.1% in the corifollitropin alfa 
and rFSH groups, respectively (P = 0.7).14 Overall, ongoing International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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pregnancy rates achieved in the ENSURE trial, also using 
the bodyweight-adjusted corifollitropin alfa dose, seemed 
to be lower than the figures achieved in the ENGAGE trial. 
Ongoing pregnancy rate per cycle was 25.4% and 34.4% 
in the corifollitropin alfa and rFSH groups, respectively. 
Although the difference was not statistically significant at the 
0.05 level (P = 0.06), the relative difference of almost 50% 
between the groups and borderline statistical significance are 
noteworthy. Given the similar stimulation characteristics in 
the two groups, ENSURE investigators consider the observed 
difference a chance finding.15 When the results from the two 
RCTs using bodyweight-adjusted gonadotropin dosages are 
combined, ongoing pregnancy rates were not significantly 
different between corifollitropin and daily rFSH groups (odds 
ratio 0.95, 95% confidence interval 0.79–1.15) (Figure 1).
Outcomes of repeated corifollitropin COS cycles
Total duration of stimulation, the numbers of COCs retrieved, 
numbers of embryos generated, good quality embryos, and 
embryos transferred were similar in the first, second, and 
third COS cycles of the TRUST trial.41 Embryo implanta-
tion, vital pregnancy and ongoing pregnancy rates seem 
consistent across fresh embryo transfer cycles. Cumulative 
ongoing pregnancy rate including spontaneous pregnancies 
and pregnancies achieved with frozen thawed embryo trans-
fer between stimulated cycles was 61% after censoring for 
women who discontinued treatment.41 Efficacy results of the 
TRUST trial are presented in Table 4.
Safety
Immunogenicity
Corifollitropin alfa is a “designer” molecule with deviated 
carbohydrate site chains that are foreign to humans. In 
theory, corifollitropin alfa can be immunogenic and lead to 
drug-related hypersensivity. It is with this concern that the 
first study in humans was performed in men with hypogo-
nadotropic hypogonadism to avoid future complications 
possibly raised by formation of cross-reactive antibodies 
against native FSH or hCG.32 No anti-corifollitropin alfa 
or anti-CHO antibodies were detected in the participants of 
this Phase I study. This finding was confirmed in over 1000 
women who received corifollitropin in other Phase II and III 
studies conducted to date.11–13,15,37
The TRUST trial assessed immunogenicity and safety 
profile of corifollitropin in detail.41 Pre- and post-treatment 
serum samples were obtained and tested for the potential anti-
corifollitropin antibodies by a validated highly sensitive assay. 
Among the post-treatment samples obtained after 682 first, 
375 second, and 192 third COS cycles, there was only one 
obtained after a second cycle that demonstrated statistically 
significantly increased binding affinity that was depletable by 
corifollitropin and rFSH, but not by recombinant LH or hCG. 
Isotyoping was technically impossible due to low titers in 
the sample. The sample actually lacked neutralizing activity 
and did not interfere with corifollitropin or rFSH bioactivity. 
The woman who provided this sample did not experience any 
adverse events (AEs), and another sample taken 6 months 
after treatment tested negative. She later conceived in a 
subsequent cycle with daily rFSH injections.
Participants of the TRUST study were systematically 
examined 30 minutes after each corifollitropin injection for 
injection site pain, itching, swelling, and redness. No drug-
related hypersensitivity reactions were reported.41 None of 
the participants had moderate or severe injection site reac-
tions. These findings are essentially the same as reported in 
the former trials.13–15
Aes
A total of 46.8%, 35.2%, and 31.3% of TRUST study 
participants reported at least one AE after cycles 1, 2, and 
3, respectively.41 Pain associated with oocyte collection 
procedure, pelvic pain, pelvic discomfort, headache, and 
Study or subgroup
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Figure 1 Ongoing pregnancy rates in trials using corifollitropin dose adjusted for bodyweight. 
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antepartum bleeding, together with mild injection site 
reactions, formed the majority of AEs. The incidence 
of these AEs in the TRUST study was similar to that in 
earlier reports.13–15 Severe AEs were uncommon, with 
incidence of 2.5%, 1.3%, and 0.5% in cycles 1, 2, and 3, 
respectively.41
A total of 63 serious AEs (SAEs) occurred in 47 par-
ticipants (6.9%) of the TRUST study.41 SAEs included eight 
ectopic pregnancies, two ruptured ectopic pregnancies, one 
heterotopic pregnancy, three missed abortions, and two immi-
nent abortions. Only 15 SAEs were attributed to the study 
medication, including 10 occurrences of ovarian hyperstimu-
lation syndrome (OHSS).41 Similarly six SAEs were reported 
in 5 of the 75 (6.7%) and 20 of the 268 (7.5%) women who 
received corifollitropin in the FS and the ENSURE trials, 
respectively.12,15 Proportion of women with SAEs were 
similar between the corifollitropin and rFSH arms in both 
the ENGAGE and ENSURE trials. Likewise, the nature of 
SAEs was similar in all studies.
Ovarian hyperstimulation syndrome
Sustained FSH levels and the inability for dose adjustment 
during the first week after corifollitropin injection raised 
concerns about OHSS risk. Increased follicular recruitment 
with corifollitropin injection as reflected by rapidly increas-
ing serum E2 levels and the higher number of .11 mm 
follicles observed within the first 6 days can justify such 
concern. Despite the fact that OHSS occurred with similar 
incidence in the corifollitropin and rFSH arms of individual 
trials (5.4% versus 8.0% in the FS, 2.6% versus 2.4% in the 
DFS, 7.0% versus 6.3% in ENGAGE, and 6.7% versus 4.7% 
in ENSURE), it should be noted that women with PCOS and 
women who had a history of OHSS had been excluded from 
all trials.12–15,41 Similarly, women who had an over response 
or OHSS in a cycle were discontinued from the TRUST 
study.41 Therefore, these observations cannot be extrapolated 
to women with the highest risk of OHSS.
Multiple pregnancy
Except monozygotic twinning, multiple pregnancy rate 
following ART is determined by the number of embryos 
transferred. Number of embryos transferred were similar 
in corifollitropin and daily rFSH arms of the reviewed tri-
als. As expected, this seems to result in similar multiple 
pregnancy rates. Multiple pregnancy rates are presented 
in Table 3.
Conclusion and future research
Corifollitropin alfa has a slower absorption rate and two-fold 
longer plasma t½ than rFSH, while maintaining the same 
pharmocodynamic activity. This allows a single injection of 
corifollitropin alfa to effectively replace the first seven daily 
injections of rFSH in COS cycles for anticipated normore-
sponder women.
The optimal corifollitropin dose has been calculated to be 
100 µg for women with a body weight # 60 kg and 150 µg 
for women with a body weight . 60 kg, respectively. Com-
bination of corifollitropin with a fixed GnRHant protocol 
starting on stimulation day 5 seems to yield at least similar 
numbers of oocytes and good quality embryos, as well as 
similar ongoing pregnancy rates compared with women 
stimulated with daily rFSH injections.
The corifollitropin molecule does not seem to be immuno-
genic. Corifollitropin seems to have a favorable safety profile 
similar to daily rFSH injections. AE, SAE, and OHSS rates 
seem to be similar. Two points should be underlined regard-
ing safety: firstly women with the highest risk of OHSS have 
been excluded from the trials and it remains to be seen how 
corifollitropin will perform in women with PCOS or high 
ovarian reserve. Secondly, as yet, there are no human data 
regarding congenital anomaly rate following corifollitropin 
stimulation available in the literature.
Further research is needed to determine whether cori-
follitropin can be used for women with anticipated poor or 
hyper-response. In theory, the increased follicular recruitment 
rate with corifollitropin can be expected to benefit poor 
responders.
It also remains to be objectively demonstrated whether 
switching to corifollitropin decreases anxiety and distress 
associated with ART.
Table 4 Efficacy results of the TRUST trial41
Cycle 1 
(n = 682)
Cycle 2 
(n = 375)
Cycle 3 
(n = 198)
Duration of stimulation 10 11 8
Number of COCs 11.9 ± 7.2 11.5 ± 6.8 11.3 ± 7.6
Number of embryos  
generated
6.4 ± 4.5 6.5 ± 4.4 6.6 ± 4.8
Number of good quality  
embryos on day 3
3.2 ± 3.1 2.9 ± 2.8 2.8 ± 2.7
Number of embryos  
transferreda
1.9 ± 0.7 2.1 ± 0.7 2.2 ± 0.7
embryo implantation ratea 21.2% 16.6% 12.2%
Ongoing pregnancy rateb 22.7% 20.5% 20.7%
Notes: aIncludes women with fresh embryo transfer; bpregnancy with 
a heart beat .10 weeks. values are mean ± standard deviation unless 
otherwise indicated.
Abbreviation: COC, cumulus corona complex.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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